Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9624082 | 0.79 | KMT2A (0.59) | TSHRHPGDSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL5476793 | 0.78 | PTGER4 (0.51) | HPGDSMN1; SMN2KDM4EHSD17B10KMT2A | |
| SCHEMBL8605369 | 0.77 | NR3C1 (0.55) | NR3C1HPGDSMN1; SMN2ARNPC1 | |
| SCHEMBL1221635 | 0.77 | MAOB (0.53) | NR3C1HPGDSMN1; SMN2ARKDM4E | |
| SCHEMBL31518588 | 0.76 | KDM4E (0.66) | TSHRHPGDSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL1221632 | 0.75 | CYP19A1 (0.50) | HPGDSMN1; SMN2ARNPC1RAB9A | |
| Acetic Acid SCHEMBL6140049 | 0.73 | BRD4 (0.65) | NR3C1HPGDSMN1; SMN2ARNPC1 | |
| SCHEMBL5203042 | 0.72 | CYP19A1 (0.64) | NR3C1HPGDSMN1; SMN2ARNPC1 | |
| SCHEMBL8605381 | 0.72 | CYP19A1 (0.54) | NR3C1HPGDSMN1; SMN2ARNPC1 | |
| SCHEMBL21436784 | 0.72 | PTPN1 (0.58) | HPGDSMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283362-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| US-20120077838-A1 | Beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077838-A1 | Beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | NR3C1 50/4885TSHR 251/4885HPGD 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.